INFLUENCE OF BONE MARROW ALLOGENEIC MULTIPOTENT MESENCHYMAL STROMAL CELLS ON THE FORMATION OF ANTI-ISCHEMIC KIDNEY PROTECTION

Аim of this work was to study the influence of intravenous injection times of bone marrow allogeneic multipotent mesenchymal stromal cells (BM MMSCs) on kidney function and morphology in modeled ischemicreperfusion injury of kidney (IRIK). Materials and methods. The study was conducted on 90 male Wistar rats. On the original IRI model of a single kidney (60 min, warm ischemia) 4 groups of experiments were performed: in the first group the dose of 5 × 106 of BM MMSCs was administered intravenously 14 days before IRIK modeling; in the second group, the same dose of BM MMSCs was administered 7 days before IRIK; in the third group, the same dose of BM MMSCs was administered during kidney reperfusion after IRIK modeling; the fourth group served as the control group (IRIK without BM МMSCs). The study duration was 21 days since the start of IRIK modeling. In all groups the nitrogen secretory function of kidneys was examined and the histological condition of kidneys during the entire recovery period was evaluated. Besides, blood of rats of the first and the fourth groups was examined for proand anti-inflammatory cytokine levels and phagocytosis indices using the suspension of inactivated St. aureus. The significance of differences in these two groups was evaluated by Student's test at p < 0.05. Results. It has been demonstrated that the pretreatment with BM MMSCs (1 and 2 weeks before IRIK modeling) increased the anti-ischemic resistance of kidney while the administration of BM MMSCs on the day of IRIK modeling (during reperfusion) enhanced kidney damage, characterized by increased mortality, elevated levels of urea and creatinine in blood and structural injury of renal tissue, as compared to other groups. The comparative analysis of the first and fourth groups shows that BM MMSCs decrease the levels of pro-inflammatory cytokines and increase the levels of anti-inflammatory cytokines, as well as enhance potential of antimicrobial protection. Conclusion. Intravenous injection of BM MMSCs 1–2 weeks prior to IRIK modeling increases the kidney resistance to ischemia, reduces the severity of the systemic inflammatory response as well as the risk of infectious complications. However, considering the possibility of the summation of the injuring influence of ischemia and the stress of the adapting doses of BM MMSCs on ischemic kidney tissue during reperfusion, the search for the optimal concentrations of BM MMSCs needs to be continued. 

1. Lebranchu Y, Bridoux F, Buchter M. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplanted patients, receiving MMFcontaining triple therapy. Am. J. Transplant. 2002; 2 (1): 48–56.

2. Hanaway MJ, Woodle ES, Mulgaonkar S. INTAC Study Group. Alemtuzumab induction in renal transplantation. N. Engl. J. Med. 2011; 364 (20): 1909–1919.

3. Dugast AS, Vanhove B. Immune regulation by non-lymphoid cells in transplantation. Clin. Exp. Immunol. 2009 Apr; 156 (1): 25–34.

4. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS et al. Perivascular origin for mesenchymal stem cells in multiple human organs. Cell, Stem cell. 2008; 3: 301–313.

5. Caplan AI. All MSC are pericytes? Cell, Stem cell. 2008; 3: 229–230.

6. Aggarwal S, Pittenger R. Human mesenchymal stem cells modulate allogenic immune cell responses. Blood. 2005; 105: 1815–1822.

7. Климович ИБ. Стволовые клетки как иммуномодуляторы при использовании клеточных технологий. Клеточные технологии для регенеративной медицины / Под ред. Г.П. Пинаева, М.С. Богдановой, А.М. Кольцовой. СПб.: Изд-во Политехнического университета, 2011; 62–86. Klimovich VB. Stem cells as immunomodulators at using of cellular technology. Cellular technology for regenerative medicine (ed. G.P. Pinaev, M.S. Bogdanova, A.M. Koltsova). SPb.: Publishing House of Polytechnical University, 2011; 62–86.

8. Hoogduijn MJ, Popp FC, Grohnert A et al. MISOT Study Group. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation. 2010; 90 (2): 124–126.

9. Cao Z, Zhang G, Wang F, Liu H, Liu L, Han Y et al. Protective effects of mesenchymal stem cells with CXCR4 up-regulation in rat renal transplantation model. PLoS One. 2013 Dec; 8 (12): e82949.

10. Baulier E, Favreau F, Le Corf A, Jayle C, Schneider F, Goujon JM et al. Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation. Stem Cells Transpl. Med. 2014 Jul; 3 (7): 809–820.

11. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012 Mar; 307 (11): 1169– 1177.

12. Lee H, Park JB, Lee S, Baek S, Kim H, Kim SJ. Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; pilot study. J. Transpl. Med. 2013 Apr; 11: 96.

13. Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W et al. Donorderived mesenchymal stem cells combined with lowdose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan; 95 (1): 161–168.

14. Perico N, Casiraghi F, Gotti E, Introna M, Todeschini M, Cavinato RA et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl. Int. 2013 Sep; 26 (9): 867–878.

15. Franquesa M, Hoogduijn MI, Baan CC. The impact of mesenchymal stem cell therapy in transplant rejection and tolerans. Curr Opin Organ Transplant. 2012 Aug; 17 (4): 355–361.

16. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerans. Curr Opin Organ Transplant. 2013 Feb; 18 (1): 51–58.

17. Aнанич ИВ, Дерхо МА, Концевая СЮ. Биохимические показатели крови у крыс. Успехи современного естествознания. 2013; 9: 29. Ananich IV, Derho MA, Kontsevaya CJu. Biochemical indices of rat blood. Uspehi sovremennogo estestvoznaniya. 2013; 9: 29.

18. Люндуп АВ. Применение мезенхимальных стромальных клеток костного мозга для коррекции фиброзирующего повреждения печени: Автореф. дис. ... канд. мед. наук. М., 2011: 26. Lyundup AV. Primenenie mezenhimal'nyh stromal'nyh kletok kostnogo mozga dlja korrekcii fibrozirujushchego povrezhdenija pecheni: Avtoref. dis. ... kand. med. nauk. M., 2011: 26.